Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.

Publication

Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.

Journal Paper/Review - Feb 2, 2022

Frei Nicola Fabian, Stachler Matthew D

Citation

Frei N, Stachler M. Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus. Visc Med 2022; 38:173-181.

Type

Journal Paper/Review (English)

Journal

Visc Med 2022; 38

Publication Date

Feb 2, 2022

Issn Print

2297-4725

Pages

173-181

Brief description/objective

A histological diagnosis of dysplasia is our current best predictor of progression in Barrett's esophagus (BE), the precursor of esophageal adenocarcinoma (EAC). Despite periodic endoscopic surveillance and assessment of dysplastic changes, we fail to identify the majority of those who progress before the development of EAC, whereas the majority of patients undergo endoscopy without showing progression.